Clinical trials: Pathological Myopia
Visual Impairment, Myopia
At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults
This study is aimed at examining the BCVA from try-on glasses constructed from measurements from the EyeQue VisionCheck.
- Conditions
- Visual Impairment, Myopia, Hyperopia, Astigmatism
- Trial name
- NCT04820218
- Testing
- With Try-on glasses
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- EyeQue Corp.
Amblyopia
Evaluation of a Smartphone Application, GoCheckKids™ as a Photo Screening Tool in a Pediatric Population
Objective: Prospective evaluation of GoCheckKids™, a smartphone application ('App') as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs) Method: Photorefraction images are captured using…
- Trial name
- NCT03119675
- Testing
- GoCheck Kids (iOS), GoCheck Kids (Windows)
- Volunteers
- 358 people
- Sponsor
- Gobiquity Mobile Health
Myopia, Hyperopia
Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
This clinical study has been planned to determine the effectiveness of a special laser treatment intended to correct both near and distance vision in patients who have undergone previous cataract surgery.
- Conditions
- Myopia, Hyperopia, Presbyopia
- Trial name
- SUPRACOR (NCT01387360)
- Testing
- Supracor
- Where
- Philippines
- Volunteers
- 33 people
- Sponsor
- Technolas Perfect Vision GmbH
Corneal Diseases
Screening Aid to Identify Corneas That May Have Pathologies or Other Conditions
The purpose of this study is to determine the ability of a proprietary software screening tool to discriminate normal corneas (front surface of the eye) from previously diagnosed corneal conditions…
- Trial name
- NCT00396188
- Where
- 4 sites in United States
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec, Inc.
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Pathological Myopic Choroidal Neovascularization
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV
- Trial name
- NCT04922151
- Testing
- 601, Ranibizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Myopia, Degenerative
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
The objectives of this study are to evaluate the safety and efficacy of 3 dose groups (27, 36 and 45 mg/m2) of Combretastatin A-4 Phosphate for the treatment of subfoveal choroidal neovascularization in subjects with pathologic…
- Trial name
- NCT01423149
- Testing
- Combretastatin A-4 Phosphate
- Volunteers
- 23 people
- Sponsor
- Mateon Therapeutics
Amblyopia
Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children
The objective is evaluation of GoCheck Kids, a smartphone application ('App'), for use as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs).
- Trial name
- NCT03447171
- Testing
- App Vision Screening
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Gobiquity Mobile Health